The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Open accessAbstract
BACKGROUND: In a phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic cancer. We conducted a phase 3 study of the efficacy and safety of the combination versus gemcitabine monotherapy in patients with metastatic pancreatic cancer. METHODS: We randomly assigned patients with a Karnofsky performance-status score of 70 or more (on a scale from 0 to 100, with higher scores indicating better performance status) to nab-paclitaxel (125 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks or gemcitabine monotherapy (1000 mg per square meter) weekly for 7 of 8 weeks (cycle 1) and then on days 1, 8, and 15 every 4 weeks (cycle 2 and subsequent cycles). Patients received the study treatment until disease progression. The primary end point was overall survival; secondary end points were progression-free survival and overall response rate. RESULTS: A total of 861 patients were randomly assigned to nab-paclitaxel plus gemcitabine (431 patients) or gemcitabine (430). The median overall survival was 8.5 months in the nab-paclitaxel-gemcitabine group as compared with 6.7 months in the gemcitabine group (hazard ratio for death, 0.72; 95% confidence interval [CI], 0.62 to 0.83; P<0.001). The survival rate was 35% in the nab-paclitaxel-gemcitabine group versus 22% in the gemcitabine group at 1 year, and 9% versus 4% at 2 years. The median progression-free survival was 5.5 months in the nab-paclitaxel-gemcitabine group, as compared with 3.7 months in the gemcitabine group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.58 to 0.82; P<0.001); the response rate according to independent review was 23% versus 7% in the two groups (P<0.001). The most common adverse events of grade 3 or higher were neutropenia (38% in the nab-paclitaxel-gemcitabine group vs. 27% in the gemcitabine group), fatigue (17% vs. 7%), and neuropathy (17% vs. 1%). Febrile neutropenia occurred in 3% versus 1% of the patients in the two groups. In the nab-paclitaxel-gemcitabine group, neuropathy of grade 3 or higher improved to grade 1 or lower in a median of 29 days. CONCLUSIONS: In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased. (Funded by Celgene; ClinicalTrials.gov number, NCT00844649.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most chemotherapy 5-7, targeted therapy 8, and immunotherapy 9-11 are ineffective because most patients are already in the progressive stage with local invasion and distant metastases at the detection time 12,13.”
From Artificial intelligence in pancreatic cancer (2022) · cites this paper as [6]
Experimental — accuracy not yet measuredIn the citing paper
“two new combination regimens have emerged as the first-line therapy in patients with advanced PDAC. The first is a combination of 5-fluorouracil (5-FU), leucovorin, irinotecan and oxaliplatin, which carries the acronym FOLFIRINOX. The second is the combination of gemcitabine and an albumin nanoparticle conjugate of paclitaxel (nab-paclitaxel)8,9.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [9]
In the citing paper
“Polychemotherapy, either with 5-fluorouracil (5-FU), irinotecan and oxaliplatin in combination with folinic acid (FOLFIRINOX), or with gemcitabine and nab-paclitaxel (GnP), is considered the standard of care for patients suffering from metastatic PDAC (mPDAC)3,4.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [3]
In the citing paper
“However, less than half of all patients are responsive to the therapy, and patients who do not respond (NR patients) suffer from pain and eventually die within weeks3.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [3]
In the citing paper
“Less than half of all patients respond to the primary treatment for PDAC, chemotherapy3,4”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [3]
In the citing paper
“patients who do not respond (NR patients) suffer from pain and eventually die within weeks3.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Self-citationMoore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Self-citationGradishar, W. J., Tjulandin, S., Davidson, N. G. P., Shaw, H., Desai, N. P., Bhar, P., Hawkins, M., & O’Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,159
Self-citationHoff, D. D. V., Ramanathan, R. K., Borad, M. J., Laheru, D. A., Smith, L. S., Wood, T. E., Korn, R. L., Desai, N. P., Trieu, V. N., Iglesias, J. L. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5742 · Cited by 1,040
Self-citationKindler, H. L., Niedzwiecki, D., Hollis, D. R., Sutherland, S., Schrag, D., Hurwitz, H. I., Innocenti, F., Mulcahy, M. F., O'Reilly, E. M., Wozniak, T. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1386 · Cited by 848
Cunningham, D., Chau, I., Stocken, D. D., Valle, J. W., Smith, D. B., Steward, W. P., Harper, P., Dunn, J., Smith, C. T., West, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2446 · Cited by 822
Chauffert, B., Mornex, F., Bonnetain, F., Rougier, P. R., Mariette, C., Bouché, O., Bosset, J.-F., Aparicio, T., Mineur, L., Azzedine, A., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn281 · Cited by 696
Philip, P. A., Benedetti, J., Corless, C. L., Wong, R., O'Reilly, E. M., Flynn, P. J., Rowland, K. M., Atkins, J. N., Mirtsching, B. C., Rivkin, S. E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7550 · Cited by 643
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,022
Oshi, M., Patel, A. P., Le, L. M., Tokumaru, Y., Yan, L., Matsuyama, R., Endo, I., & Takabe, K. (2021) · PubMed Central · Cited by 58
Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present
Huff, S. E., Winter, J. M., & Dealwis, C. G. (2022) · Biomolecules · doi:10.3390/biom12060815 · Cited by 58
Current trends in the use of human serum albumin for drug delivery in cancer
Paul, M., Itoo, A. M., Ghosh, B., & Biswas, S. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2134341 · Cited by 58
Cao, F., LI, J., Sun, H., LIU, S., Cui, Y., & Li, F. (2015) · Oncology Reports · doi:10.3892/or.2015.3789 · Cited by 58
Serrano, P. E., Cleary, S. P., Dhani, N. C., Kim, P. T. W., Greig, P. D., Leung, K. S.-S., Moulton, C.-A. E., Gallinger, S., & Wei, A. C.-C. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4196-2 · Cited by 58
The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer
Xiong, G., Feng, M., Yang, G., Zheng, S., Song, X., Cao, Z., You, L., Zheng, L., Hu, Y., Zhang, T., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.02.020 · Cited by 58
Liu, C., Cheng, H., Luo, G., Yu, L., Jin, K., Guo, M., Ni, Q., & Yu, X. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4032 · Cited by 58
van der Geest, L. G., Mohammad, N. H., Besselink, M. G., Lemmens, V. E. P. P., Portielje, J. E. A., van Laarhoven, H. W. M., Wilmink, J. W., & the Dutch Pancreatic Cancer Group (2017) · Cancer Medicine · doi:10.1002/cam4.1240 · Cited by 58
Liu, X., Li, C., Li, J., Yu, T., Zhou, G., Cheng, J., Li, G., Zhou, Y., Lou, W., Wang, X., et al. (2018) · Journal of Cancer · doi:10.7150/jca.23989 · Cited by 58
Veenstra, V. L., Damhofer, H., Waasdorp, C., van Rijssen, L. B., van de Vijver, M. J., Dijk, F., Wilmink, H. W., Besselink, M. G., Busch, O. R., Chang, D. K.-F., et al. (2018) · Oncogenesis · doi:10.1038/s41389-018-0096-9 · Cited by 58
Dong, R., Chen, P., Polireddy, K., Wu, X., Wang, T., Ramesh, R., Dixon, D. A., Xu, L., Aubé, J., & Chen, Q. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0822 · Cited by 58
A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?
Katayama, E., Hue, J. J., Bajor, D. L., Ocuin, L. M., Ammori, J. B., Hardacre, J. M., & Winter, J. M. (2020) · Oncotarget · doi:10.18632/oncotarget.27727 · Cited by 58
Bazzichetto, C., Luchini, C., Conciatori, F., Vaccaro, V., Cello, I. D., Mattiolo, P., Falcone, I., Ferretti, G., Scarpa, A., Cognetti, F., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228841 · Cited by 58
Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs
Kokkinos, J., Ignacio, R. M. C., Sharbeen, G., Boyer, C. A., Gonzales‐Aloy, E., Goldstein, D., Initiative, A. P. C. G., McCarroll, J. A., & Phillips, P. A. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119742 · Cited by 57
Self-citationKandimalla, R., Tomihara, H., Banwait, J. K., Yamamura, K., Singh, G. P., Baba, H., & Goel, A. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4044 · Cited by 57
Fu, X., Zhang, X., Huang, D., Mao, L., Qiu, Y., & Zhao, Y. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.133362 · Cited by 57
Multimodal survival prediction in advanced pancreatic cancer using machine learning
Keyl, J., Kasper, S., Wiesweg, M., Götze, J., Schönrock, M., Sinn, M., Berger, A., Nasca, E., Kostbade, K., Schumacher, B. M., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100555 · Cited by 57
Extracellular GPX4 impairs antitumor immunity via dendritic ZP3 receptors
Liu, J., Cai, X., Lin, J., Zhang, Z., Zhou, Q., Zhang, X., Ma, L., Miao, Y., Zhang, R., Yu, C., et al. (2026) · Cell · doi:10.1016/j.cell.2025.12.002 · Cited by 59
Song, B. S., Seo, J., Kim, D. H., Lim, J. S., Yoo, J. Y., & Lee, J. A. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25035 · Cited by 57
Cys34-PEGylated Human Serum Albumin for Drug Binding and Delivery
Mehtala, J. G., Kulczar, C. D., Lavan, M., Knipp, G. T., & Wei, A. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00143 · Cited by 57
Shaib, W. L., Hawk, N. N., Cassidy, R. J., Chen, Z., Zhang, C., Brutcher, E., Kooby, D. A., Maithel, S. K., Sarmiento, J. M., Landry, J. C., et al. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.05.010 · Cited by 57
Targeting Cancer using Polymeric Nanoparticle mediated Combination Chemotherapy
Gad, A. (2016) · International Journal of Nanomedicine and Nanosurgery · doi:10.16966/2470-3206.116 · Cited by 57
BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo
Kumar, K., DeCant, B. T., Grippo, P. J., Hwang, R. F., Bentrem, D. J., Ebine, K., & Munshi, H. G. (2017) · JCI Insight · doi:10.1172/jci.insight.88032 · Cited by 57
Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations
Guo, S., Contratto, M., Miller, G., Leichman, L., & Wu, J. J. (2017) · World Journal of Clinical Oncology · doi:10.5306/wjco.v8.i3.230 · Cited by 57
Robert, M., Jarlier, M., Gourgou, S., Desseigne, F., Ychou, M., Bouché, O., Juzyna, B., Conroy, T., & Bennouna, J. (2017) · Oncology · doi:10.1159/000477850 · Cited by 57
Camblin, A. J., Pace, E. A., Adams, S., Curley, M. D., Rimkunas, V. M., Nie, L., Tan, G., Bloom, T., Iadevaia, S., Baum, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2262 · Cited by 57
Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations
Ozaki, T., Yu, M., Yin, D., Sun, D., Zhu, Y., Bu, Y., & Sang, M. (2018) · BMC Cancer · doi:10.1186/s12885-018-4217-9 · Cited by 57
Environmental Risk Factors of Pancreatic Cancer
Tsai, H., & Chang, J. S.-M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091427 · Cited by 57
Pietrasz, D., Renault, S., Taı̈eb, J., Dahan, L., Postel, M., Durand-Labrunie, J., Malicot, K. L., Mulot, C., Rinaldi, Y., Phelip, J., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01624-2 · Cited by 56
Yang, X., Zhang, J., Zhou, Q.-M., Yu, J., Lu, Y., Wang, X., Zhou, J.-P., Ding, X.-F., Du, Y., & Yu, R. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01738-6 · Cited by 56
Nanoparticles in the diagnosis and treatment of cancer metastases: Current and future perspectives
Hegde, M., Naliyadhara, N., Unnikrishnan, J., Alqahtani, M. S., Abbas, M. A. E., Girisa, S., Sethi, G., & Kunnumakkara, A. B. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216066 · Cited by 56
Microbiota in cancer: current understandings and future perspectives
Yao, Y., Zhu, Y., Chen, K., Chen, J., Li, Y., Li, D., & Wei, P. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02335-3 · Cited by 56
Vena, F., Causi, E. L., Rodriguez‐Justo, M., Goodstal, S. M., Hagemann, T., Hartley, J. A., & Hochhauser, D. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0485 · Cited by 56
Pancreatic cancer: diagnosis and treatments
Li, H., Cui, Z.-M., Jiang, C., Guo, X., & Li, Y. (2015) · Tumor Biology · doi:10.1007/s13277-015-3223-7 · Cited by 56
Şahin, İ. H., Lowery, M. A., Stadler, Z. K., Salo‐Mullen, E. E., Iacobuzio–Donahue, C. A., Kelsen, D. P., & O'Reilly, E. M. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1153424 · Cited by 56
Sho, M., Murakami, Y., Kawai, M., Motoi, F., Satoi, S., Matsumoto, I., Honda, G., Uemura, K., Yanagimoto, H., Kurata, M., et al. (2016) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.320 · Cited by 56
Moyer, M. T., Dye, C. E., Sharzehi, S., Ancrile, B., Mathew, A., McGarrity, T. J., Gusani, N. J., Yee, N. S., Wong, J. Y., Levenick, J. M., et al. (2016) · Endoscopy International Open · doi:10.1055/s-0042-105431 · Cited by 56
Kowalski, S., Hać, S., Wyrzykowski, D., Zauszkiewicz–Pawlak, A., & Inkielewicz‐Stępniak, I. (2017) · Oncotarget · doi:10.18632/oncotarget.19454 · Cited by 56
MiR-203a-3p Inhibits Pancreatic Cancer Cell Proliferation, EMT, and Apoptosis by Regulating SLUG
An, N., & Zheng, B. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033819898729 · Cited by 56
Sunami, Y., Boeker, V., & Kleeff, J. H. (2021) · Cancers · doi:10.3390/cancers13040697 · Cited by 56
Riedl, J. M., Posch, F., Horvath, L., Gantschnigg, A., Renneberg, F., Schwarzenbacher, E., Moik, F., Barth, D. A., Rossmann, C. H., Stotz, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.040 · Cited by 56
The role of endoscopic ultrasound in pancreatic cancer screening
Bhutani, M., Koduru, P., Joshi, V., Saxena, P., Suzuki, R., Irisawa, A., & Yamao, K. (2016) · Endoscopic Ultrasound · doi:10.4103/2303-9027.175876 · Cited by 55
Vogl, U. M., Andalibi, H., Klaus, A., Vormittag, L., Schima, W., Heinrich, B., Kafka, A., Winkler, T., & Öhler, L. (2019) · BMC Cancer · doi:10.1186/s12885-018-5240-6 · Cited by 55
PARP Inhibitors in Pancreatic Cancer
Brown, T. J., & Reiss, K. A. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000554 · Cited by 55
Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma
Wang, X., Zhang, C., Dong, X., Hu, Y., Duan, B., Bai, J., Wu, Y., Fan, L., Liao, X.-H., Kang, Y., et al. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i7.1252 · Cited by 55
Capula, M., Perán, M., Xu, G., Donati, V. L., Yee, D., Gregori, A., Assaraf, Y. G., Giovannetti, E., & Deng, D. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100864 · Cited by 55
Mercanti, L., Sindaco, M., Mazzone, M., Marcantonio, M. C. D., Piscione, M., Muraro, R., & Mincione, G. (2023) · Cancers · doi:10.3390/cancers15112923 · Cited by 55
Pradhan, R., Kundu, A., & Kundu, C. N. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104311 · Cited by 55
Current and Emerging Treatment Options for Pancreatic Cancer: A Comprehensive Review
Hayat, U., Croce, P., Saadeh, A., Desai, K., Appiah, J., Khan, S., Khan, Y. I., Kumar, K., & Hanif, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041129 · Cited by 55
Bai, X., Zhi, X., Zhang, Q., Liang, F., Chen, W., Liang, C., Hu, Q., Sun, X., Zhuang, Z., & Liang, T. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.09.048 · Cited by 55
Stotz, M., Szkandera, J., Seidel, J., Stojaković, T., Samonigg, H., Reitz, D., Gary, T., Kornprat, P., Schaberl-Moser, R., Höefler, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104730 · Cited by 55
Locally Advanced Pancreatic Cancer: The Role of Definitive Chemoradiotherapy
Huguet, F., Mukherjee, S., & Javle, M. M. (2014) · Clinical Oncology · doi:10.1016/j.clon.2014.06.002 · Cited by 55
A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma
Indolfi, L., Ligorio, M., Ting, D. T., Xega, K., Tzafriri, A. R., Bersani, F., Aceto, N., Thapar, V., Fuchs, B. C., Deshpande, V., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.03.044 · Cited by 55
Valero, V., Saunders, T., He, J. P., Weiss, M. J., Cameron, J. L., Dholakia, A. S., Wild, A. T., Shin, E. J., Khashab, M. A., Lennon, A. M., et al. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000001156 · Cited by 55
Self-citationNitschke, P., Volk, A., Welsch, T., Hackl, J. A., Reißfelder, C., Rahbari, M., Distler, M., Saeger, H., Weitz, J., & Rahbari, N. N. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001808 · Cited by 55
Murakami, Y., Uemura, K., Sudo, T., Hashimoto, Y., Kondo, N., Nakagawa, N., Takahashi, S., & Sueda, T. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3199-z · Cited by 55
Ottaiano, A., Capozzi, M., Divitiis, C. D., Stefano, A. D., Botti, G., Avallone, A., & Tafuto, S. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1288922 · Cited by 55
A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer
Coppola, S., Carnevale, I., Danen, E. H. J., Peters, G. J., Schmidt, T., Assaraf, Y. G., & Giovannetti, E. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.07.001 · Cited by 55
Short- and Long-Term Survival in Metastatic Pancreatic Adenocarcinoma, 1993–2013
Golan, T., Sella, T., Margalit, O., Amit, U., Halpern, N., Aderka, D., Shacham‐Shmueli, E., Urban, D., & Lawrence, Y. R. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0138 · Cited by 55
Thibodeau, S., & Voutsadakis, I. A. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7010007 · Cited by 55
Gajiwala, S., Torgeson, A. M., Garrido‐Laguna, I., Kinsey, C. G., & Lloyd, S. A. J. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.05.16 · Cited by 55
El‐Zahaby, S. A., Elnaggar, Y. S. R., & Abdallah, O. Y. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.11.013 · Cited by 55
Mackay, T. M., van Erning, F. N., van der Geest, L. G., de Groot, J. W. B., Mohammad, N. H., Lemmens, V. E. P. P., van Laarhoven, H. W. M., Besselink, M. G., & Wilmink, J. W. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.008 · Cited by 55
Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer
Hiroshima, Y., Fukumitsu, N., Saito, T., Numajiri, H., Murofushi, K. N., Ohnishi, K., Nonaka, T., Ishikawa, H., Okumura, T., & Sakurai, H. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.03.012 · Cited by 55
Kshattry, S., Saha, A., Gries, P., Tiziani, S., Stone, E. M., Georgiou, G., & DiGiovanni, J. (2019) · npj Precision Oncology · doi:10.1038/s41698-019-0088-z · Cited by 54
Nabavizadeh, A., Payen, T., Iuga, A. C., Sagalovskiy, I. R., Desrouilleres, D., Saharkhiz, N., Palermo, C. F., Sastra, S. A., Oberstein, P. E., Rosario, V. L., et al. (2020) · Theranostics · doi:10.7150/thno.37965 · Cited by 55
Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer
Mavros, M. N., Moris, D., Karanicolas, P. J., Katz, M. H. G., O'Reilly, E. M., & Pawlik, T. M. (2021) · JAMA Surgery · doi:10.1001/jamasurg.2021.0149 · Cited by 55
Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer
Manegold, P., Lai, K., Wu, Y., Teo, J.-L., Lenz, H.-J., Genyk, Y., Pandol, S., Wu, K., Lin, D., Chen, Y., et al. (2018) · Cancers · doi:10.3390/cancers10040095 · Cited by 51
HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1
Lu, Y., Xu, D., Peng, J., Luo, Z., Chen, C., Chen, Y., Chen, H., Zheng, M., Yin, P., & Wang, Z. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.05.013 · Cited by 54
Poh, A. R., & Ernst, M. (2023) · Oncogene · doi:10.1038/s41388-023-02701-x · Cited by 54
Clinical immunotherapy in pancreatic cancer
Ye, X., Yu, Y., Zheng, X., & Ma, H. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03632-6 · Cited by 54
Philip, P. A., Sahai, V., Bahary, N., Mahipal, A., Kasi, A., Lima, C. M. S. R., Alistar, A. T., Oberstein, P. E., Golan, T., Metges, J., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02659 · Cited by 54
Self-citationMannucci, A., & Goel, A. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70035 · Cited by 54
Huo, Y., Yang, M., Liu, W., Yang, J., Fu, X., Liu, D., Li, J., Zhang, J., Hua, R., & Sun, Y. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0202-1 · Cited by 54
Sun, J. D., Liu, Q., Ahluwalia, D., Li, W., Meng, F., Wang, Y., Bhupathi, D., Ruprell, A. S., & Hart, C. P. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2014.1003005 · Cited by 54
Mohammad, N. H., Bernards, N., Besselink, M. G., Busch, O. R., Wilmink, J. W., Creemers, G. J. M., de Hingh, I. H. J. T., Lemmens, V. E. P. P., & van Laarhoven, H. W. M. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2140-5 · Cited by 54
Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer
Abrams, T. A., Meyer, G. E., Meyerhardt, J. A., Wolpin, B. M., Schrag, D., & Fuchs, C. S. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0447 · Cited by 54
Mondal, G., Almawash, S., Chaudhary, A., & Mahato, R. I. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00355 · Cited by 54
Naqvi, I. A., Gunaratne, R., McDade, J. E., Moreno, A., Rempel, R. E., Rouse, D. C., Herrera, S. G., Pisetsky, D. S., Lee, J., White, R. R., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.018 · Cited by 54
Management of Borderline Resectable Pancreatic Cancer
Toesca, D. A. S., Koong, A. J., Poultsides, G. A., Visser, B. C., Haraldsdóttir, S., Koong, A. C., & Chang, D. T. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.12.287 · Cited by 54
Emerging strategies in BRCA-positive pancreatic cancer
Kowalewski, A., Szylberg, Ł., Saganek, M., Napiontek, W., Antosik, P., & Grzanka, D. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2666-9 · Cited by 54
Pancreatic Cancer–Induced Cachexia and Relevant Mouse Models
Henderson, S. E., Makhijani, N., & Mace, T. A. (2018) · Pancreas · doi:10.1097/mpa.0000000000001124 · Cited by 54
Shi, S., Liang, C., Xu, J., Meng, Q., Hua, J., Yang, X., Ni, Q., & Yu, X. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002998 · Cited by 54
Kundranda, M. N., Gracián, A. C., Zafar, S. F., Meiri, E., Bendell, J. C., Algül, H., Rivera, F., Ahn, E. R., Watkins, D. J., Pelzer, U., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.09.004 · Cited by 54
Kang, H., Jo, J. H., Lee, H. S., Chung, M. J., Bang, S., Park, S. W., Song, S. Y., & Park, J. Y. (2018) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v10.i11.421 · Cited by 54
Parkin, A., Man, J., Timpson, P., & Pajic, M. (2019) · FEBS Journal · doi:10.1111/febs.15011 · Cited by 54
Hua, Y., Zhu, Y., Xie, G., Zhang, K., Sheng, J., Zhu, Z., Ning, Z., Chen, H., Chen, Z., Meng, Z., et al. (2019) · Aging · doi:10.18632/aging.102307 · Cited by 54
Takeda, T., Sasaki, T., Suzumori, C., Mie, T., Furukawa, T., Yamada, Y., Kasuga, A., Matsuyama, M., Ozaka, M., & Sasahira, N. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01912-0 · Cited by 54
Ahmad, R. S., Eubank, T. D., Łukomski, S., & Boone, B. A. (2021) · Biomolecules · doi:10.3390/biom11060901 · Cited by 53
Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1
Wattenberg, M. M., Coho, H., Herrera, V. M., Graham, K. L., Stone, M. L., Xue, Y., Chang, R. B., Cassella, C. R., Liu, M., Choi-Bose, S., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adj5097 · Cited by 53
Treating Alzheimer’s disease using nanoparticle-mediated drug delivery strategies/systems
Roghani, A. K., Garcia, R. I., Roghani, A., Reddy, A. P., Khemka, S., Reddy, R. P., Pattoor, V., Jacob, M., Reddy, P. H., & Sehar, U. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102291 · Cited by 53
Clinical Applications of Targeted Nanomaterials
Kumar, A., Shahvej, S., Yadav, P. K., Modi, U., Yadav, A. K., Solanki, R., & Bhatia, D. D. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030379 · Cited by 53
Control of Apoptosis in Treatment and Biology of Pancreatic Cancer
Modi, S., Kir, D., Banerjee, S., & Saluja, A. K. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25284 · Cited by 53
Ohkawa, S., Okusaka, T., Isayama, H., Fukutomi, A., Yamaguchi, K., Ikeda, M., Funakoshi, A., Nagase, M., Hamamoto, Y., Nakamori, S., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.103 · Cited by 53
Goldstein, D., Hoff, D. D. V., Moore, M. J., Greeno, E. W., Tortora, G., Ramanathan, R. K., Macarulla, T. M., Liu, H. W., Pilot, R., Ferrara, S., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.10.017 · Cited by 53
Self-citationDotan, E., Alpaugh, R. K., Ruth, K. J., Negin, B. P., Denlinger, C. S., Hall, M. J., Astsaturov, I. A., McAleer, C., Fittipaldi, P., Thrash-Bingham, C., et al. (2016) · Pancreas · doi:10.1097/mpa.0000000000000619 · Cited by 53
Park, I., Choi, S. J., Kim, Y. S., Ahn, H. K., Hong, J., Sym, S. J., Park, J., Cho, E. K., Lee, J. H., Shin, Y. J., et al. (2016) · Cancer Research and Treatment · doi:10.4143/crt.2015.250 · Cited by 53
Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer
Bakrania, A. K., Variya, B. C., & Patel, S. S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.023 · Cited by 53
Akita, H., Takahashi, H., Ohigashi, H., Tomokuni, A., Kobayashi, S., Sugimura, K., Miyoshi, N., Moon, J.-H., Yasui, M., Omori, T., et al. (2017) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.03.015 · Cited by 53
Metadata
- Authors
- Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., Harris, M., Reni, M., Dowden, S., Laheru, D., Bahary, N., Ramanathan, R. K., Tabernero, J., Hidalgo, M., Goldstein, D., Van Cutsem, E., Wei, X., Iglesias, J., & Renschler, M. F.
- Affiliations
- University of Washington (US)
- Tennessee Oncology (US)
- Princess Margaret Cancer Centre (CA)
- Russian Cancer Research Center NN Blokhin (RU)
- Translational Genomics Research Institute (US)
- Georgia Cancer Specialists (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- University of Pittsburgh Medical Center (US)
- Universitat Autònoma de Barcelona (ES)
- Prince of Wales Hospital (AU)
- Celgene (United States) (US)
- Bionomics (Australia) (AU)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-31
- Volume
- 369
- Issue
- 18
- Pages
- 1691-1703
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4631139
- OpenAlex
- W2165480504
- Cited by
- 6,712
- References
- 23
- Citations by year
- 2026: 403 · 2025: 491 · 2024: 537 · 2023: 607 · 2022: 614 · 2021: 695 · 2020: 631 · 2019: 531 · 2018: 548 · 2017: 512 · 2016: 423 · 2015: 424 · 2014: 271 · 2013: 15
- FWCI
- 200.89
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- pancreatic cancer, metastatic pancreatic cancer, nab-paclitaxel, gemcitabine, combination chemotherapy, gemcitabine monotherapy, overall survival, progression-free survival, overall response rate, treatment safety, adverse events, chemotherapy schedule, Karnofsky performance status
- MeSH terms
- Gemcitabine, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Albumins, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Female, Humans, Male, Middle Aged, Nervous System Diseases, Neutropenia, Pancreatic Neoplasms, Paclitaxel, Disease-Free Survival, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
